SAN DIEGO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- (“Aardvark”) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate ...

Aardvark Therapeutics, Inc. ("Aardvark") (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics ...

Metsera, Inc. (Nasdaq: MTSR) (“Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone (NuSH) analog peptides to treat obesity, ...

As part of the transaction Tether purchased 103,333,333 shares of Rumble Class A Common Stock at a price per share of $7.50, totaling $775 million in gross proceeds to Rumble. The Company will use ...

It's been a limp February so far for the crypto market, despite the amount of positive news for the sector stemming from the ...

Truist Securities maintained their Hold rating on Shopify shares (NYSE:SHOP), with a steady price target of $120.00, close to the current trading price of $119.43. Following the release of the company ...

A pair of drugmakers priced their initial public offerings on Thursday, delivering the best month for US health care ...

Phathom Pharmaceuticals (PHAT) stock rises as Cantor Fitzgerald issues an Overweight rating, rejecting its IP-rights related ...

Cantor Fitzgerald upgraded CVS Health (NYSE:CVS) to Overweight from Neutral and increased its 12-month per-share target to $71 from $62 on Wednesday after the managed care giant delivered better ...

Cantor Fitzgerald has a “Neutral” rating and a $110.00 price objective on the stock. The consensus estimate for Fortinet’s current full-year earnings is $2.05 per share. Get Fortinet alerts: ...

Cantor Fitzgerald currently has a $170.00 price objective on the biotechnology company’s stock. Other analysts also recently issued research reports about the stock. StockNews.com upgraded ...